AU2017229445B2 - Novel inhibitors of phosphatidylinositol 3-kinase gamma - Google Patents

Novel inhibitors of phosphatidylinositol 3-kinase gamma Download PDF

Info

Publication number
AU2017229445B2
AU2017229445B2 AU2017229445A AU2017229445A AU2017229445B2 AU 2017229445 B2 AU2017229445 B2 AU 2017229445B2 AU 2017229445 A AU2017229445 A AU 2017229445A AU 2017229445 A AU2017229445 A AU 2017229445A AU 2017229445 B2 AU2017229445 B2 AU 2017229445B2
Authority
AU
Australia
Prior art keywords
oxo
dihydro
acetamide
methyl
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017229445A
Other languages
English (en)
Other versions
AU2017229445A1 (en
Inventor
Rhona Cox
Konstantinos Karabelas
Mickael Mogemark
Nils Pemberton
Matthew Perry
Jens Petersen
Christian Tyrchan
Pavol Zlatoidsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2017229445A1 publication Critical patent/AU2017229445A1/en
Application granted granted Critical
Publication of AU2017229445B2 publication Critical patent/AU2017229445B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017229445A 2016-03-10 2017-03-09 Novel inhibitors of phosphatidylinositol 3-kinase gamma Ceased AU2017229445B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306328P 2016-03-10 2016-03-10
US62/306,328 2016-03-10
PCT/EP2017/055552 WO2017153527A1 (en) 2016-03-10 2017-03-09 Novel inhibitors of phosphatidylinositol 3-kinase gamma

Publications (2)

Publication Number Publication Date
AU2017229445A1 AU2017229445A1 (en) 2018-10-25
AU2017229445B2 true AU2017229445B2 (en) 2019-07-11

Family

ID=58264542

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017229445A Ceased AU2017229445B2 (en) 2016-03-10 2017-03-09 Novel inhibitors of phosphatidylinositol 3-kinase gamma

Country Status (13)

Country Link
US (2) US10858355B2 (enExample)
EP (1) EP3426652B1 (enExample)
JP (1) JP6893520B2 (enExample)
KR (1) KR20180117693A (enExample)
CN (1) CN108779110B (enExample)
AR (1) AR107840A1 (enExample)
AU (1) AU2017229445B2 (enExample)
BR (1) BR112018068075A2 (enExample)
CA (1) CA3015893C (enExample)
EA (1) EA036388B1 (enExample)
MX (1) MX387125B (enExample)
TW (1) TWI746525B (enExample)
WO (1) WO2017153527A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) * 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020210379A1 (en) 2019-04-10 2020-10-15 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors
AU2020288610A1 (en) 2019-06-04 2022-01-27 Arcus Biosciences, Inc. 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
CN115611883B (zh) * 2021-07-13 2025-03-28 生物岛实验室 一种双环结构的PI3Kα抑制剂及其制备方法和用途
CN119768404A (zh) * 2022-09-01 2025-04-04 上海海雁医药科技有限公司 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
EP4585596A4 (en) * 2022-09-09 2025-12-10 Shanghai Yingli Pharm Co Ltd Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
EP4734987A1 (en) 2023-06-30 2026-05-06 Forschungsverbund Berlin E.V. Thiazolo tetrahydrochinoline compounds as class ii phosphoinositide 3-kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087776A1 (en) * 2009-12-22 2011-07-21 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2015048318A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
AU2007207743B2 (en) * 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
JP2009535386A (ja) * 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
CA2752596A1 (en) * 2009-02-17 2010-08-26 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
CN104379573A (zh) * 2012-04-20 2015-02-25 艾伯维公司 异吲哚酮衍生物
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087776A1 (en) * 2009-12-22 2011-07-21 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2015048318A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Also Published As

Publication number Publication date
EA201891931A1 (ru) 2019-04-30
EA036388B1 (ru) 2020-11-03
TW201808945A (zh) 2018-03-16
WO2017153527A1 (en) 2017-09-14
US10858355B2 (en) 2020-12-08
US20210047312A1 (en) 2021-02-18
BR112018068075A2 (pt) 2019-01-08
JP6893520B2 (ja) 2021-06-23
JP2019507788A (ja) 2019-03-22
KR20180117693A (ko) 2018-10-29
AR107840A1 (es) 2018-06-13
MX2018010894A (es) 2018-11-09
MX387125B (es) 2025-03-18
US20200299289A1 (en) 2020-09-24
EP3426652A1 (en) 2019-01-16
CA3015893C (en) 2021-11-09
CN108779110A (zh) 2018-11-09
CA3015893A1 (en) 2017-09-14
AU2017229445A1 (en) 2018-10-25
CN108779110B (zh) 2021-10-29
TWI746525B (zh) 2021-11-21
EP3426652B1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
CA3015893C (en) Novel inhibitors of phosphatidylinositol 3-kinase gamma
WO2023086350A1 (en) Alkyne-containing antiviral agents
AU2017331940B2 (en) 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 H-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma
CA3150689A1 (en) Heterocyclic compounds as kinase inhibitors
WO2017001853A1 (en) Antiviral compounds
RS58374B1 (sr) Inhibitori dnk-pk
KR20150054994A (ko) 브루톤 티로신 키나아제의 억제제
WO2018228934A1 (en) Heteroaromatic compounds as vanin inhibitors
CN116670133A (zh) α 蛋白激酶1抑制剂及使用方法
WO2016197078A1 (en) Compounds for the modulation of myc activity
KR102858857B1 (ko) 오렉신 수용체 길항제로서의 치환된 2-아자바이사이클로[3.1.1]헵탄 및 2-아자바이사이클로[3.2.1]옥탄 유도체
TW202325282A (zh) 一種五員并六員化合物、製備方法、藥物組成物和應用
KR101707761B1 (ko) 브루톤 티로신 키나아제 억제제로서의 티아졸 유도체
EA033571B1 (ru) Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
HK1257837A1 (en) Novel inhibitors of phosphatidylinositol 3-kinase gamma
HK1220190B (en) Dna-pk inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired